Beyond Meat's Executive Shakeup Signals Deeper Turnaround as AlixPartners Takes the Reins

Beyond Meat hands day-to-day operations to AlixPartners' John Boken as COO exits; debt slashed to $411M, but revenue shrinks and stock nears all-time low.

The restructuring at Beyond Meat is accelerating, with an external turnaround specialist now effectively running the company's day-to-day operations. COO Jonathan Nelson will step down on May 17, 2026, handing the reins to John Boken, a 63-year-old interim executive already serving as Chief Transformation Officer via the consultancy AlixPartners. Boken will absorb the COO duties into his existing mandate at no extra cost — a move that underscores just how embedded AlixPartners has become in the troubled plant-based protein maker.

The leadership change comes as Beyond Meat continues to wrestle with a brutal demand slump. First-quarter volumes collapsed by nearly a fifth year-on-year, with restaurant sales — both domestically and internationally — plunging over 30% as diners balked at premium pricing on menus. The retail channel held up better, but not enough to offset the damage. Net revenue for the opening quarter landed at roughly $58 million, while the net loss, though cut in half year-on-year to $28.5 million, remained steep. On a non-GAAP basis, the loss came in at $46.8 million, down from $59 million in the prior-year period.

As part of the broader operational overhaul, the company has also installed Tony Kalajian as chief accounting officer, swapping out CFO Lubi Kutua from his interim controller role. Kalajian received stock options on approximately 238,000 shares plus nearly 180,000 restricted stock units. The management reshuffle follows the belated April filing of Beyond Meat's annual report, which had been delayed after the company flagged weaknesses in its inventory accounting.

Beyond Meat's balance sheet offers limited comfort. Through aggressive restructuring, the company has slashed its debt pile from over $1 billion to $411 million, while cash and equivalents stand at roughly $205 million. Yet the stock continues to languish near its all-time low of around $0.80, having swung between $0.50 and $7.69 over the past year. The market is clearly not convinced the turnaround is taking hold.

In a bid to generate new revenue streams, Beyond Meat is abandoning the Chinese market entirely and pivoting to functional beverages. This summer, it will launch "Beyond Immerse," a lightly carbonated drink packed with protein and electrolytes, explicitly targeting consumers of GLP-1 medications. A distribution deal with Big Geyser opens up tens of thousands of outlets in the New York metro area. The company is betting that the beverage line can plug some of the hole left by its shrinking core business.

But near-term visibility remains poor. Management has guided for second-quarter revenue of $60 million to $65 million, a range that falls short of the $67 million analysts had penciled in. The New York beverage rollout will be a crucial test: if "Beyond Immerse" fails to gain traction, the options for a meaningful operational recovery will shrink even further.